Piperidine based MCH antagonists for treatment of obesity and CNS disorders

A compound of formula I:

• or a pharmaceutically acceptable salt or solvate of said compound, wherein:
• Ar1 is aryl, heteroaryl, (R7)p-substituted aryl or (R7)p-substituted heteroaryl, wherein p is a number from 1 to 5 and when p is more than 1, each R7 can be the same or different and each R7 is hydrogen or independently selected from the group consisting of OH, alkoxy, CN, halogen, NR8R9, C(O)NR8R9, N(R8)C(O)R5, N(R8)S(O2)R5, S(O2)NR8R9, C(O)OR8, OCF3, CF3, S(O2)R5 and C(O)R5, or two adjacent R7 can be joined together to form an alkylenedioxy selected from
• or when Ar1 is an (R7)p-substituted aryl, where R7 and the phenyl ring to which it is shown attached in Formula I can be bridged by Y as shown by
• R1 is H, alkyl, aryl, aralkyl, aryloxyalkyl, hydroxyalkyl, alkoxyalkyl, heteroaryl, (styrenyl)methyl, heteroaralkyl, cycloalkylalkyl, heterocyclyl, cycloalkyl, wherein each of said alkyl, aralkyl, aryloxyalkyl, hydroxyalkyl, alkoxyalkyl, heteroaralkyl, cycloalkylalkyl, heterocyclyl and cycloalkyl can be unsubstituted or optionally substituted with one or more R7 moieties which can be the same or different, —S(O2)NR8R9, S(O2)R5, C(O)OR8, C(O)R5, C(O)NR8R9, (R7)p-substituted aryl or (R7)p-substituted heteroaryl, wherein p is a number from 1 to 5 and when p is more than 1, each R7 can be the same or different and each R7 is hydrogen or independently selected from the group consisting of alkyl, cycloalkyl, OH, alkoxy, CN, halogen, heteroaryl, OC(O)OH;
• aryloxy, NR8R9, C(O)NR8R9, N(R8)C(O)R5, N(R8)S(O2)R5, S(O2)NR8R9, C(O)OR8, OCF3, CF3, SR5, S(O2)R5 and C(O)R5, or two adjacent R7 can be joined together to form an alkylenedioxy selected from
• R2, R3, R8 and R9 can each be the same or different and each independently H or alkyl;
• or R2 and R3 together are alkylene and with the carbon to which they are attached form a 3 to 7 membered ring;
• R4 is H, alkyl, aralkyl, R5C(O), R5S(O2) or
• R5 is alkyl or aryl;
• R6 is alkyl, aralkyl or (R7)p-substituted aralkyl, wherein p is a number from 1 to 5 and when p is more than 1, each R7 can be the same or different and each R7 is hydrogen or independently selected from the group consisting of OH, alkoxy, CN, halogen, NR8R9, C(O)NR8R9, N(R8)C(O)R5, N(R8)S(O2)R5, —S(O2)NR8R9, C(O)OR8, OCF3, CF3, S(O2)R5 and C(O)R5,
• R10 is aryl, heteroaryl, (R7)p-substituted aryl or (R7)p-substituted heteroaryl, wherein p is a number from 1 to 5 and when p is more than 1, each R7 can be the same or different and each R7 is hydrogen or independently selected from the group consisting of OH, alkoxy, CN, halogen, NR8R9, C(O)NR8R9, N(R8)C(O)R5, N(R8)S(O2)R5, S(O2)NR8R9, C(O)OR8, OCF3, CF3, S(O2)R5, C(O)R5 and heterocycloalkyl or R10 is an alkylene or heteroalkylene where said alkylene or heteroalkylene is attached to the N of NR10 to form a heterocyclyl ring selected from the group consisting of
• X is N(R4), O, S, S→O, S(O2), C(O) or CH2;
• Y is O, CH2, C(O), N(H), N(R6) or S;
• k is 0, 1 or 2;
• m is 0, 1 or 2;
• n is 0 or 2;
• and
• wherein each of said alkyl, alkylene, heteroalkylene, aryl, aralkyl, alkoxy, arylyoxy, aryloxyalkyl, hydroxyalkyl, alkoxyalkyl, heterocyclyl, heterocycloalkyl, heteroaryl, heteroaralkyl, cycloalkylalkyl, heterocyclyl and cycloalkyl can be unsubstituted or optionally substituted with one or more R7 moieties which can be the same or different.